Experiment 66771

Compounds isolated

Details

PropertyValue
Pharmacology
Administration routeORAL
OrganismEmpty organism
CitationCASTANO,G: MAS,R: FERNANDEZ,JC: FERNANDEZ,L: ALVAREZ,E: LEZCAY,M:. (2000). EFFICACY AND TOLERABILITY OF POLICOSANOL COMPARED WITH LOVASTATIN IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND CONCOMITANT CORONARY RISK FACTORS.. 61(3)
Amount utilized
Compound isolated
DiseaseTHIS RANDOMIZED, DOUBLE-BLIND STUDY WAS UNDERTAKEN TO COMPARE THE EFFICACY AND TOLERABILITY OF POLICOSANOL 10 MG/D AND LOVASTATIN 20 MG/D IN PATIENT WITH TYPE II HYPERCHOLESTEROLEMIA WHO WERE AT HIGH RISK FOR CORONARY EVENTS. AFTER 4 WEEKS ON A LIPID-LOWERING DIET, 59 PATIENTS WHO MET STUDY CONDUCT CRITERIA WERE ASSIGNED RANDOMLY TO RECEIVE, IN A DOUBLE-BLIND TRIAL, POLICOSANOL OR LOVASTATIN TABLETS QD FOR 12 WEEKS. POLICOSANOL SIGNIFICANTLY (P<0.00001) REDUCED LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) (32.4%), TOTAL CHOLESTEROL (TC) (22.4%), AND THE RATIOS OF LDL-C/HIGH-DENSITY-LIPOPROTEIN CHOLESTEROL (HDL-C) (39.3%) AND TC/HDL-C (32.0%). LOVASTATIN SIGNIFICANTLY (P<0.0001) REDUCED LDL-C (27.6%), TC (19.8%), AND THE RATIOS (P<0.001) OF LDLD-C/HDL-C (32.8%) AND TC/HDL-C (25.2%). POLICOSANOL SIGNIFICANTLY (P<0.05) INCREASED LEVELS OF HDL-C (14.3%); LOVASTATIN TREATMENT DID NOT SIGNIFICANTLY AFFECT HDL-C LEVELS. BETWEEN-GROUP COMPARISONS THUS SHOWED THAT POLICOSANOL WAS MORE EFFECTIVE (P<0.05) THAN LOVASTATIN IN REDUCING THE LDL-C/HDL-C RATIO AND INCREASING HDL-C LEVELS. BOTH TREATMENTS WERE WELL TOLERATED. WE CONCLUDED THAT POLICOSANOL 10 MG/D AND LOVASTATIN 20 MG/D WERE SIMILARY EFFECTIVE AND WELL TOLERATED IN TREATING PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA AND CONCOMITANT MULTIPLE CORONORY RISK FACTORS. MODEST ADVANTAGES WERE SHOWN WITH REGARD TO THE CHANGES IN HDL-C LEVELS AND THE LDL-C/HDL-C RATIO.
Dose amount10.0 MG
Number1
Qualitative resultACTIVE
AnimalHUMAN ADULT
Dose expressionDOSE
GenderGIVEN TO BOTH SEXES